ERBB2 and neoplasm: Identification of HER2‐positive tumours with active HER2 oncogenic activity through a clinically applicable and cost‐effective tool is mandatory for prediction of patients who would benefit the most from HER2 signalling pathway targeting therapy, both in the neoadjuvant and adjuvant settings [45, 46, 47, 48, 49].